Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors

Current Medicinal Chemistry

Volumn 22, Issue 13, 2015, Pages 1573-1581

  Matteucci, E ^a   Giampietro, O ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Alzheimer disease; Diabetes mellitus; Dipeptidyl peptidase 4 inhibitors; Parkinson disease; Vascular dementia

Indexed keywords

ALOGLIPTIN; CALCITONIN GENE RELATED PEPTIDE; CHEMOKINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIN RELEASING PEPTIDE; GLUCAGON LIKE PEPTIDE 1; HYDROLASE; INCRETIN; INTERMEDIN; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; NEUROPEPTIDE; NEUROPEPTIDE Y; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ARTICLE; CELL CULTURE; DEGENERATIVE DISEASE; DIABETES MELLITUS; DIFFUSE LEWY BODY DISEASE; ENERGY METABOLISM; GLUCAGON RELEASE; HEART INFARCTION; MULTIINFARCT DEMENTIA; NERVE CELL DEGENERATION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PARKINSON DISEASE; ANIMAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; HUMAN; METABOLISM; NEURODEGENERATIVE DISEASES;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS;

EID: 84931292010     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150227153308     Document Type: Article

References (91)

1. McKhann, G.; Drachman, D.; Folstein, M.; Katzman, R.; Price, D.; Stadlan, E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 1984, 34, 939-944.
2. McKhann, G.M.; Knopman, D.S.; Chertkow, H.; Hyman, B.T.; Jack, C.R. Jr.; Kawas, C.H.; Klunk, W.E.; Koroshetz, W.J.; Manly, J.J.; Mayeux, R.; Mohs, R.C.; Morris, J.C.; Rossor, M.N.; Scheltens, P.; Carrillo, M.C.; Thies, B.; Weintraub, S.; Phelps, C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement., 2011, 7, 263-269.
3. Jack, C.R. Jr.; Knopman, D.S.; Jagust, W.J.; Petersen, R.C.; Weiner, M.W.; Aisen, P.S.; Shaw, L.M.; Vemuri, P.; Wiste, H.J.; Weigand, S.D.; Lesnick, T.G.; Pankratz, V.S.; Donohue, M.C.; Trojanowski, J.Q. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol., 2013, 12, 207-216.
4. Dawkins, E.; Small, D.H. Insights into the physiological function of the ß-amyloid precursor protein: beyond Alzheimer's disease. J. Neurochem., 2014, 129, 756-769.
5. Scholz, T.; Mandelkow, E. Transport and diffusion of Tau protein in neurons. Cell. Mol. Life Sci., 2014, 71(16): 3139-3150.
6. Román, G.C.; Tatemichi, T.K.; Erkinjuntti, T.; Cummings, J.L.; Masdeu, J.C.; Garcia, J.H.; Amaducci, L.; Orgogozo, J.M.; Brun, A.; Hofman, A. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology, 1993, 43, 250-260.
7. Gardner, R.C.; Valcour, V.; Yaffe, K. Dementia in the oldest old: A multi-factorial and growing public health issue. Alzheimers Res. Ther., 2013, 5, 27.
8. Narkiewicz, J.; Giachin, G.; Legname, G. In vitro aggregation assays for the characterization of α-synuclein prion-like properties. Prion, 2014, 8, 19-32.
9. Berg, D.; Postuma, R.B.; Bloem, B.; Chan, P.; Dubois, B.; Gasser, T.; Goetz, C.G.; Halliday, G.M.; Hardy, J.; Lang, A.E.; Litvan, I.; Marek, K.; Obeso, J.; Oertel, W.; Olanow, C.W.; Poewe, W.; Stern, M.; Deuschl, G. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov. Disord., 2014, 29, 454-462.
10. Profenno, L.A.; Porsteinsson, A.P.; Faraone, S.V. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol. Psychiatry, 2010, 67, 505-512.
11. Cereda, E.; Barichella, M.; Pedrolli, C.; Klersy, C.; Cassani, E.; Caccialanza, R.; Pezzoli, G. Diabetes and risk of Parkinson's disease: A systematic review and meta-analysis. Diabetes Care, 2011, 34, 2614-2623.
12. Cheng, G.; Huang, C.; Deng, H.; Wang, H. Diabetes as a risk factor for dementia and mild cognitive impairment: A meta-analysis of longitudinal studies. Intern. Med. J., 2012, 42, 484-491.
13. Noyce, A.J.; Bestwick, J.P.; Silveira-Moriyama, L.; Hawkes, C.H.; Giovannoni, G.; Lees, A.J.; Schrag, A. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann. Neurol., 2012, 72, 893-901.
14. Ahtiluoto, S.; Polvikoski, T.; Peltonen, M.; Solomon, A.; Tuomilehto, J.; Winblad, B.; Sulkava, R.; Kivipelto, M. Diabetes, Alzheimer disease, and vascular dementia: A population-based neuropathologic study. Neurology, 2010, 75, 1195-1202.
15. Ohara, T.; Doi, Y.; Ninomiya, T.; Hirakawa, Y.; Hata, J.; Iwaki, T.; Kanba, S.; Kiyohara, Y. Glucose tolerance status and risk of dementia in the community: The Hisayama study. Neurology, 2011, 77, 1126-1134.
16. Wang, K.C.; Woung, L.C.; Tsai, M.T.; Liu, C.C.; Su, Y.H.; Li, C.Y. Risk of Alzheimer's disease in relation to diabetes: A population-based cohort study. Neuroepidemiology, 2012, 38, 237-244.
17. Cheng, P.Y.; Sy, H.N.; Wu, S.L.; Wang, W.F.; Chen, Y.Y. Newly diagnosed type 2 diabetes and risk of dementia: A population-based 7-year follow-up study in Taiwan. J. Diabetes Complications, 2012, 26, 382-387.
18. Thambisetty, M.; Jeffrey Metter, E.; Yang, A.; Dolan, H.; Marano, C.; Zonderman, A.B.; Troncoso, J.C.; Zhou, Y.; Wong, D.F.; Ferrucci, L.; Egan, J.; Resnick, S.M.; O'Brien, R.J. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol., 2013, 70, 1167-1172.
19. Haring, B.; Leng, X.; Robinson, J.; Johnson, K.C.; Jackson, R.D.; Beyth, R.; Wactawski-Wende, J.; von Ballmoos, M.W.; Goveas, J.S.; Kuller, L.H.; Wassertheil-Smoller, S. Cardiovascular disease and cognitive decline in postmenopausal women: results from the Women's Health Initiative Memory Study. J. Am. Heart Assoc., 2013, 2, e000369.
20. Roberts, R.O.; Knopman, D.S.; Geda, Y.E.; Cha, R.H.; Pankratz, V.S.; Baertlein, L.; Boeve, B.F.; Tangalos, E.G.; Ivnik, R.J.; Mielke, M.M.; Petersen, R.C. Association of diabetes with amnestic and nonamnestic mild cognitive impairment. Alzheimers Dement., 2014, 10, 18-26.
21. DeFronzo, R.A.; Ferrannini, E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care, 1993, 14, 173-194.
22. Tuomilehto, J.; Rastenyte, D.; Jousilahti, P.; Sarti, C., Vartiainen, E. Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. Stroke, 1996, 27, 210-215.
23. Huang, E.S.; Laiteerapong, N.; Liu, J.Y.; John, P.M.; Moffet, H.H.; Karter, A.J. Rates of complications and mortality in older patients with diabetes mellitus: The diabetes and aging study. JAMA Intern. Med., 2014, 174, 251-258.
24. Exalto, L.G.; Biessels, G.J.; Karter, A.J.; Huang, E.S.; Quesenberry, Jr. C.P.; Whitmer, R.A. Severe Diabetic Retinal Disease and Dementia Risk in Type 2 Diabetes. J. Alzheimers Dis., 2014, 42(Suppl. 3): 109-117.
25. Vermeer, S.E.; Prins, N.D.; den Heijer, T.; Hofman, A.; Koudstaal, P.J.; Breteler, M.M. Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med., 2003, 348, 1215-1222.
26. Rincon, F.; Wright, C.B. Current pathophysiological concepts in cerebral small vessel disease. Front. Aging Neurosci., 2014, 6, 24.
27. Petrovitch, H.; Ross, G.W.; Steinhorn, S.C.; Abbott, R.D.; Markesbery, W.; Davis, D.; Nelson, J.; Hardman, J.; Masaki, K.; Vogt, M.R.; Launer, L.; White, L.R. AD lesions and infarcts in demented and non-demented Japanese-American men. Ann. Neurol., 2005, 57, 98-103.
28. Brundel, M.; Kappelle, L.J.; Biessels, G.J. Brain imaging in type 2 diabetes. Eur. Neuropsychopharmacol., 2014, 24(12): 1967-1981.
29. Feinkohl, I.; Aung, P.P.; Keller, M.; Robertson, C.M.; Morling, J.R.; McLachlan, S.; Deary, I.J.; Frier, B.M.; Strachan, M.W.; Price, J.F.; Edinburgh Type 2 Diabetes Study (ET2DS) Investigators. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: The Edinburgh type 2 diabetes study. Diabetes Care, 2014, 37, 507-515.
30. Crane, P.K.; Walker, R.; Hubbard, R.A.; Li, G.; Nathan, D.M.; Zheng, H.; Haneuse, S.; Craft, S.; Montine, T.J.; Kahn, S.E.; McCormick, W.; McCurry, S.M.; Bowen, J.D.; Larson, E.B. Glucose levels and risk of dementia. N. Engl. J. Med., 2013, 369, 540-548.
31. Morris, J.K.; Vidoni, E.D.; Honea, R.A.; Burnsm J.M.; Alzheimer's Disease Neuroimaging Initiative. Impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol. Aging., 2014, 35, 585-589.
32. Kielstein, J.T. Glucose levels and risk of dementia. N. Engl. J. Med., 2013, 369, 1863.
33. Li, J.; Liu, D.; Sun, L.; Lu, Y.; Zhang, Z. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J. Neurol. Sci., 2012, 317, 1-5.
34. Wan, W.; Chen, H.; Li, Y. The potential mechanisms of Aβ-receptor for advanced glycation end-products interaction disrupting tight junctions of the blood-brain barrier in Alzheimer's disease. Int. J. Neurosci., 2014, 124, 75-81.
35. Chen, S.; An, F.M.; Yin, L.; Liu, A.R.; Yin, D.K.; Yao, W.B.; Gao, X.D. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation. Neuroscience, 2014, 256, 137-146.
36. Chen, Y.; Deng, Y.; Zhang, B.; Gong, C.X. Deregulation of brain insulin signaling in Alzheimer's disease. Neurosci. Bull., 2014, 30, 282-294.
37. de la Monte, S.M.; Tong, M. Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem. Pharmacol., 2014, 88, 548-559.
38. Santiago, J.A.; Potashkin, J.A. System-based approaches to decode the molecular links in Parkinson's disease and diabetes. Neurobiol. Dis,. 2014, 72 PtA: 84-91.
39. Hill, B.G.; Benavides, G.A.; Lancaster, J.R.Jr.; Ballinger, S.; Dell'Italia, L.; Jianhua, Z.; Darley-Usmar, V.M. Integration of cellular bioenergetics with mitochondrial quality control and autophagy. Biol. Chem., 2012, 393, 1485-1512.
40. Matteucci, E.; Giampietro, O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr. Med. Chem., 2009, 16, 2943-2951.
41. Matteucci, E.; Giampietro, O. Dipeptidyl peptidase-4 inhibition: linking chemical properties to clinical safety. Curr. Med. Chem., 2011, 18, 4753-4760.
42. Lone, A.M.; Nolte, W.M.; Tinoco, A.D.; Saghatelian, A. Peptidomics of the prolyl peptidases. AAPS J., 2010, 12, 483-491.
43. Mannucci, E.; Pala, L.; Ciani, S.; Bardini, G.; Pezzatini, A.; Sposato, I.; Cremasco, F.; Ognibene, A.; Rotella, C.M. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia, 2005, 48, 1168-1172.
44. Darsalia, V.; Nathanson, D.; Nyström, T.; Klein, T.; Sjöholm, A.; Patrone, C. GLP-1R activation for the treatment of stroke: updating and future perspectives. Rev. Endocr. Metab. Disord., 2014, 15, 233-242.
45. Hölscher, C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol., 2014, 221, T31-41.
46. Shannon, R.P. DPP-4 inhibition and neuroprotection: do mechanisms matter? Diabetes, 2013, 62, 1029-1031
47. Sharoyan, S.; Antonyan, A.; Mardanyan, S.; Harutyunyan, H.; Movsisyan, N.; Hovnanyan, N.; Hovnanyan, K. Interaction of dipeptydil peptidase IV with amyloid peptides. Neurochem. Int., 2013, 62, 1048-1054.
48. Deacon, C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: A comparative review. Diabetes Obes. Metab., 2011, 13, 7-18.
49. Pintana, H.; Apaijai, N.; Chattipakorn, N.; Chattipakorn, S.C. DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. J. Endocrinol., 2013, 218, 1-11.
50. Tarragó, T.; Masdeu, C.; Gómez, E.; Isambert, N.; Lavilla, R.; Giralt, E. Benzimidazolium salts as small, nonpeptidic and BBBpermeable human prolyl oligopeptidase inhibitors. ChemMed-Chem., 2008, 3, 1558-1565.
51. Rawlings, N.D.; Waller, M.; Barrett, A.J.; Bateman, A. MEROPS: The database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res., 2014, 42, D503-509.
52. Lee, E.H.; Seo, S.R. Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases. B.M.B. Rep., 2014, 47, 369-375.
53. Campolongo, P.; Ratano, P.; Ciotti, M.T.; Florenzano, F.; Nori, S.L.; Marolda, R.; Palmery, M.; Rinaldi, A.M.; Zona, C.; Possenti, R.; Calissano, P.; Severini, C. Systemic administration of substance P recovers beta amyloid-induced cognitive deficits in rat: involvement of Kv potassium channels. PLoS One., 2013, 8, e78036.
54. Wang, Q.; Chu, C.H.; Qian, L.; Chen, S.H.; Wilson, B.; Oyarzabal, E.; Jiang, L.; Ali, S.; Robinson, B.; Kim, H.C.; Hong, J.S. Substance P exacerbates dopaminergic neurodegeneration through neurokinin-1 receptor-independent activation of microglial NADPH oxidase. J. Neurosci., 2014, 34, 12490-12503.
55. Wang, Q.; Xu, Y.; Chen, J.C.; Qin, Y.Y.; Liu, M.; Liu, Y.; Xie, M.J.; Yu, Z.Y.; Zhu, Z.; Wang, W. Stromal cell-derived factor 1α decreases β-amyloid deposition in Alzheimer's disease mouse model. Brain Res., 2012, 1459, 15-26.
56. Walton, N.M.; de Koning, A.; Xie, X.; Shin, R.; Chen, Q.; Miyake, S.; Tajinda, K.; Gross, A.K.; Kogan, J.H.; Heusner, C.L.; Tamura, K.; Matsumoto, M. Gastrin-releasing peptide contributes to the regulation of adult hippocampal neurogenesis and neuronal development. Stem Cells., 2014, 32, 2454-2466.
57. Zaheer, S.; Thangavel, R.; Wu, Y.; Khan, M.M.; Kempuraj, D.; Zaheer, A. Enhanced expression of glia maturation factor correlates with glial activation in the brain of triple transgenic Alzheimer's disease mice. Neurochem. Res., 2013, 38, 218-225.
58. Tousi, N.S.; Buck, D.J.; Curtis, J.T.; Davis, R.L. α-Synuclein potentiates interleukin-1β-induced CXCL10 expression in human A172 astrocytoma cells. Neurosci. Lett., 2012, 507, 133-136.
59. Savolainen, M.H.; Richie, C.T.; Harvey, B.K.; Männistö, P.T.; Maguire-Zeiss, K.A.; Myöhänen, T.T. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse. Neurobiol. Dis., 2014, 68, 1-15.
60. (a) Duez, H.; Cariou, B.; Staels, B. DPP-4 inhibitors in the treatment of type 2 diabetes. Biochem. Pharmacol., 2012, 83, 823-832;
61. (b) Gitt, A.K.; Bramlage, P.; Binz, C.; Krekler, M.; Deeg, E.; Tschöpe, D. Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting-results of the 1 year follow-up of the prospective DiaRegis registry. Int. J. Clin. Pract., 2013, 67, 1005-1014.
62. Paneni, F.; Beckman, J.A.; Creager, M.A.; Cosentino, F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur. Heart J., 2013, 34, 2436-2443.
63. Wu, S.; Hopper, I.; Skiba, M.; Krum, H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: Meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc. Ther., 2014, 32(4): 147-158.
64. Patil, H.R.; Al Badarin, F.J.; Al Shami, H.A.; Bhatti, S.K.; Lavie, C.J.; Bell, D.S.; O'Keefe, J.H. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am. J. Cardiol., 2012, 110, 826-833.
65. Monami, M.; Ahrén, B.; Dicembrini, I.; Mannucci, E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: A meta-analysis of randomized clinical trials. Diabetes Obes. Metab., 2013, 15, 112-120.
66. dos Santos, L.; Salles, T.A.; Arruda-Junior, D.F.; Campos, L.C.; Pereira, A.C.; Barreto, A.L.; Antonio, E.L.; Mansur, A.J.; Tucci, P.J.; Krieger, J.E.; Girardi, A.C. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circ. Heart Fail., 2013, 6, 1029-1038.
67. Gomez, N.; Touihri, K.; Matheeussen, V.; Mendes Da Costa, A.; Mahmoudabady, M.; Mathieu, M.; Baerts, L.; Peace, A.; Lybaert, P.; Scharpé, S.; De Meester, I.; Bartunek, J.; Vanderheyden, M.; Mc Entee, K. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur. J. Heart Fail., 2012, 14, 14-21.
68. Sauvé, M.; Ban, K.; Momen, M.A.; Zhou, Y.Q.; Henkelman, R.M.; Husain, M.; Drucker, D.J. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes, 2010, 59, 1063-1073.
69. Huisamen, B.; Genis, A.; Marais, E.; Lochner, A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, prediabetic rats. Cardiovasc. Drugs Ther., 2011, 25, 13-20.
70. Fujiwara, T.; Yoshida, M.; Nakamura, T.; Sakakura, K.; Wada, H.; Arao, K.; Katayama, T.; Funayama, H.; Sugawara, Y.; Mitsuhashi, T.; Kakei, M.; Momomura, S.I.; Ako, J. Dipeptidyl peptidase-4 inhibitors are associated with improved left ventricular diastolic function after acute myocardial infarction in diabetic patients. Heart Vessels, 2014 [Epub ahead of print].
71. Matheeussen, V.; Jungraithmayr, W.; De Meester, I. Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. Pharmacol. Ther., 2012, 136, 267-282.
72. Monami, M.; Lamanna, C.; Desideri, C.M.; Mannucci, E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv. Ther., 2012, 29, 14-25.
73. Dicker, D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care, 2011, 34, S276-S278.
74. Mason, R.P.; Jacob, R.F.; Kubant, R.; Ciszewski, A.; Corbalan, J.J.; Malinski, T. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J. Cardiovasc. Pharmacol., 2012, 60, 467-473.
75. Shah, Z.; Pineda, C.; Kampfrath, T.; Maiseyeu, A.; Ying, Z.; Racoma, I.; Deiuliis, J.; Xu, X.; Sun, Q.; Moffatt-Bruce, S.; Villamena, F.; Rajagopalan, S. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul. Pharmacol., 2011, 55, 2-9.
76. Crajoinas, R.O.; Oricchio, F.T.; Pessoa, T.D.; Pacheco, B.P.; Lessa, L.M.; Malnic, G.; Girardi, A.C. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am. J. Physiol. Renal Physiol., 2011, 301, F355-F363.
77. Pacheco, B.P.; Crajoinas, R.O.; Couto, G.K.; Davel, A.P.; Lessa, L.M.; Rossoni, L.V.; Girardi, A.C. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J. Hypertens., 2011, 29, 520-528.
78. Ishibashi, Y.; Matsui, T.; Maeda, S.; Higashimoto, Y.; Yamagishi, S. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc. Diabetol., 2013, 12, 125.
79. Lamers, D.; Famulla, S.; Wronkowitz, N.; Hartwig, S.; Lehr, S.; Ouwens, D.M.; Eckardt, K.; Kaufman, J.M.; Ryden, M.; Müller, S.; Hanisch, F.G.; Ruige, J.; Arner, P.; Sell, H.; Eckel, J. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes, 2011, 60, 1917-1925.
80. Pipatpiboon, N.; Pintana, H.; Pratchayasakul, W.; Chattipakorn, N.; Chattipakorn, S.C. DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption. Eur. J. Neurosci., 2013, 37, 839-849.
81. Jozwiak-Bebenista, M.; Dejda, A.; Nowak, J.Z. Effects of PACAP, VIP and related peptides on cyclic AMP formation in rat neuronal and astrocyte cultures and cerebral cortical slices. Pharmacol. Rep., 2007, 59, 414-420.
82. Lau, B.Y.; Fogerson, S.M.; Walsh, R.B.; Morgan, J.R. Cyclic AMP promotes axon regeneration, lesion repair and neuronal survival in lampreys after spinal cord injury. Exp. Neurol., 2013, 250, 31-42.
83. Werner, H.; LeRoith, D. Insulin and insulin-like growth factor receptors in the brain: physiological and pathological aspects. Eur. Neuropsychopharmacol., 2014, 24, 1947-1953.
84. Mattson, M.P. Interventions that improve body and brain bioenergetics for Parkinson's disease risk reduction and therapy. J. Parkinsons. Dis., 2014, 4, 1-13
85. Gray, S.M.; Meijer, R.I.; Barrett, E.J. Insulin regulates brain function, but how does it get there? Diabetes, 2014, 63, 3992-3997.
86. D'Amico, M.; Di Filippo, C.; Marfella, R.; Abbatecola, A.M.; Ferraraccio, F.; Rossi, F.; Paolisso, G. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp. Gerontol., 2010, 45, 202-207.
87. Kosaraju, J.; Murthy, V.; Khatwal, R.B.; Dubala, A.; Chinni, S.; Muthureddy Nataraj, S.K.; Basavan, D. Vildagliptin: an antidiabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. J. Pharm. Pharmacol., 2013, 65, 1773-1784.
88. Kosaraju, J.; Gali, C.C.; Khatwal, R.B.; Dubala, A.; Chinni, S.; Holsinger, R.M.; Madhunapantula, S.V.; Muthureddy Nataraj, S.K.; Basavan, D. Saxagliptin: A dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. Neuropharmacology, 2013, 72, 291-300.
89. Kosaraju, J.; Madhunapantula, S.V.; Chinni, S.; Khatwal, R.B.; Dubala, A.; Muthureddy Nataraj, S.K.; Basavan, D. Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana ameliorates streptozotocin induced Alzheimer's disease. Behav. Brain Res., 2014, 267, 55-65.
90. Nassar, N.N.; Al-Shorbagy, M.Y.; Arab, H.H.; Abdallah D.M. Saxagliptin: A novel antiparkinsonian approach. Neuropharmacology, 2014, 89C, 308-317.
91. Darsalia, V.; Olverling, A.; Larsson, M.; Mansouri, S.; Nathanson, D.; Nyström, T.; Klein, T.; Sjöholm, A.; Patrone, C. Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice. Regul. Pept., 2014, 190-191, 25-31.